News

Dynavax has met with the European Medicines Evaluation Agency (EMEA) to discuss its plans for continued clinical development of HEPLISAV phase 3 investigational adult hepatitis B vaccine in

Clinical Data has entered into a collaboration and licensing agreement with CombinatoRx to develop an adenosine A2A agonist compound in a combination therapy. It is intended for the

The US Food and Drug Administration has accepted to file Theratechnologies’ New Drug Application (NDA) for its lead compound, tesamorelin. Under the terms of the company’s collaboration and

Cannabis Science has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials.

Astellas has received the notice that FDA has substantially denied the company’s Citizen Petition, which had been submitted on September 2007, to ensure the safe and effective use

Light Sciences Oncology (LSO) has reported the treatment of the first patient in phase 1 pediatric study of its novel light-activated drug Aptocine (talaporfin sodium) in neurofibromatosis type

Bristol-Myers Squibb has reported the expiration of Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex. The expiration of the HSR waiting period satisfies one of the

Hana Biosciences (Hana) has achieved its enrollment goal of 56 evaluable subjects in the pivotal phase 2 rALLy clinical trial for Marqibo (vincristine sulfate liposomes injection). It is

Arrayit said that Arrayit Diagnostics Inc. will spearhead an intensive marketing campaign in an effort to establish Arrayit in the diagnostics sector.